Literature DB >> 31517568

β-Sitosterol Shows Potential to Protect Against the Development of High-Fructose Diet-Induced Metabolic Dysfunction in Female Rats.

Nontobeko M Gumede1, Busisani W Lembede1, Richard L Brooksbank1, Kennedy H Erlwanger1, Eliton Chivandi1.   

Abstract

Metabolic syndrome (MetS) is a combination of risk factors that include insulin resistance, obesity, dyslipidemia, and hypertension. The consumption of high-fructose diets contributes to the development of MetS. β-sitosterol a naturally occurring phytosterol possesses antiobesogenic and antidiabetic effects. This study evaluated the potential protective effect of β-sitosterol against the development of metabolic dysfunction in growing female rats fed a high-fructose diet, mimicking children fed obesogenic diets. Thirty-five 21-day-old female Sprague Dawley rat pups were randomly allocated to and administered the following treatments: group 1-standard rat chow (SRC) + plain drinking water (PW) + plain gelatine cube (PC); group 2-SRC + 20% w/w fructose solution (FS) as drinking fluid + PC; group 3-SRC + FS + 100 mg/kg fenofibrate in gelatine cubes; group 4-SRC + FS + 20 mg/kg β-sitosterol gelatine cube (Bst); and group 5-SRC + PW + Bst. Following 12 weeks of feeding, the rats were fasted overnight, weighed, and then euthanized. Plasma cholesterol, insulin, glucose, triglyceride, and adiponectin concentrations were determined. Visceral fat was dissected out and weighed. The high-fructose diet increased (P < .05) visceral adiposity and plasma triglyceride concentration but decreased (P < .05) plasma adiponectin concentration. β-sitosterol prevented the high-fructose diet-induced visceral obesity, hypertriglyceridemia, and hypoadiponectinemia. β-sitosterol alone increased plasma adiponectin concentration and reduced plasma insulin concentration and homeostatic model assessment index. In conclusion, β-sitosterol could be potentially used to prevent high-fructose diet-induced metabolic dysfunction.

Entities:  

Keywords:  adiponectin; dyslipidemia; fructose; insulin resistance; metabolic syndrome; β-sitosterol

Mesh:

Substances:

Year:  2019        PMID: 31517568     DOI: 10.1089/jmf.2019.0120

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  5 in total

Review 1.  The Role of Phytosterols in Nonalcoholic Fatty Liver Disease.

Authors:  Otilia Frasinariu; Roxana Serban; Laura Mihaela Trandafir; Ingrith Miron; Magdalena Starcea; Ioana Vasiliu; Anna Alisi; Oana Raluca Temneanu
Journal:  Nutrients       Date:  2022-05-24       Impact factor: 6.706

2.  Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.

Authors:  Guozhen Yuan; Shuai Shi; Qiulei Jia; Jingjing Shi; Shuqing Shi; Xuesong Zhang; Xintian Shou; Xueping Zhu; Yuanhui Hu
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-16       Impact factor: 2.629

3.  Lupeol reduces M1 macrophage polarization to attenuate immunologic dissonance and fatty acid deposition in rats with diet-induced metabolic syndrome.

Authors:  Jin Li; Yuechen Huang; Yue Han; Jiafu Wang; Chun Zhang; Jiuyang Jiang
Journal:  Ann Transl Med       Date:  2021-10

4.  Zebrafish obesogenic test identifies anti-adipogenic fraction in Moringa oreifera leaf extracts.

Authors:  Izumi Matsuoka; Kanae Hata; Hirotaka Katsuzaki; Hiroko Nakayama; Liqing Zang; Mizuho Ota; Youngil Kim; Djong-Chi Chu; Lekh Raj Juneja; Norihiro Nishimura; Yasuhito Shimada
Journal:  Food Sci Nutr       Date:  2022-02-11       Impact factor: 2.863

5.  Dietary Supplementation with Chestnut (Castanea sativa) Reduces Abdominal Adiposity in FVB/n Mice: A Preliminary Study.

Authors:  Pedro Rodrigues; Tiago Ferreira; Elisabete Nascimento-Gonçalves; Fernanda Seixas; Rui Miguel Gil da Costa; Tânia Martins; Maria João Neuparth; Maria João Pires; Germano Lanzarin; Luís Félix; Carlos Venâncio; Isabel C F R Ferreira; Margarida M S M Bastos; Rui Medeiros; Isabel Gaivão; Eduardo Rosa; Paula A Oliveira
Journal:  Biomedicines       Date:  2020-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.